Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
| Autor: | H.H. Lervang, T. Le-Thi, B Brock, Sten Madsbad, O Schmitz, Tina Vilsbøll, Thure Krarup, Milan Zdravkovic, Hans Perrild, K Kølendorf, K Levin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Type 2 diabetes Incretins Drug Administration Schedule chemistry.chemical_compound Islets of Langerhans Endocrinology Insulin resistance Glucagon-Like Peptide 1 Diabetes mellitus Internal medicine Internal Medicine medicine Receptors Glucagon Humans Hypoglycemic Agents Pancreatic hormone C-Peptide business.industry C-peptide Liraglutide Insulin Middle Aged medicine.disease Glucagon-like peptide-1 Treatment Outcome chemistry Diabetes Mellitus Type 2 Female Insulin Resistance business medicine.drug |
| Zdroj: | Vilsbøll, T, Brock, B, Perrild, H, Levin, K, Lervang, H H, Kølendorf, K E, Krarup, T, Schmitz, O, Zdravkovic, M, Le-Thi, T & Madsbad, S 2008, ' Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. ', Diabetic Medicine, vol. 25, no. 2, pp. 152-6 . https://doi.org/10.1111/j.1464-5491.2007.02333.x |
| DOI: | 10.1111/j.1464-5491.2007.02333.x |
| Popis: | Udgivelsesdato: 2008-Feb AIMS: To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test. RESULTS: The two highest doses of liraglutide (1.25 and 1.9 mg/day) significantly increased first-phase insulin secretion by 118 and 103%, respectively (P < 0.05). Second-phase insulin secretion was significantly increased only in the 1.25 mg/day group vs. placebo. Arginine-stimulated insulin secretion increased significantly at the two highest dose levels vs. placebo by 114 and 94%, respectively (P < 0.05). There was no significant treatment effect on glucose effectiveness or insulin sensitivity. CONCLUSIONS: Fourteen weeks of treatment with liraglutide showed improvements in first- and second-phase insulin secretion, together with improvements in arginine-stimulated insulin secretion during hyperglycaemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|